MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results ...

Blue chip stocks are under immense pressure amid the evolving trade tensions and tariff announcements around the globe.

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid an escalating trade war between ...

A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus (HPV) vaccines Gardasil and Gardasil 9, marking a continued setback for the company’s ...

A new study seems to confirm that a single dose of the vaccine used to prevent HPV infection is just as effective as two — ...

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

Market volatility has led to compelling dividend opportunities, and Merck and Schlumberger offer great value at low PE ratios ...

In its first-quarter results update, MSD – which is known as Merck & Co in the US and Canada – said it expects full-year ...

On an earnings call in February, he answered question after question about plunging demand for his company’s vaccine against ...

Find insight on Merck, Sanofi and more in the latest Market Talks covering the Health Care sector.